Therapeutic benefits targeting B-cells in chronic graft-versus-host disease

@article{Nakasone2015TherapeuticBT,
  title={Therapeutic benefits targeting B-cells in chronic graft-versus-host disease},
  author={Hideki Nakasone and Bita Sahaf and David B. Miklos},
  journal={International Journal of Hematology},
  year={2015},
  volume={101},
  pages={438-451}
}
Allogeneic hematopoietic cell transplantation (allo-HCT) can be a curative strategy for hematological diseases, and the indications for allo-HCT have broadened widely due to recent progress in supportive strategies. However, patients must overcome various complications and chronic graft-versus-host disease (cGVHD) remains the most common allo-HCT cause of long-term morbidity and mortality. cGVHD is difficult to biologically assess due to the heterogeneity of cGVHD symptoms, and the pathogenesis… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-9 OF 9 CITATIONS

References

Publications referenced by this paper.
SHOWING 1-10 OF 106 REFERENCES

Proteasome inhibition and allogeneic hematopoietic stem cell transplantation: a review.

  • Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • 2009
VIEW 7 EXCERPTS
HIGHLY INFLUENTIAL

National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report.

  • Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • 2005
VIEW 5 EXCERPTS
HIGHLY INFLUENTIAL

Allogeneic HY antibodies 3 months following female to male sex-mismatched HCT predicts chronic GVHD and non-relapse mortality

H Nakasone, L Tian, B Sahaf
  • Blood. 2015 [Epub ahead of print]
  • 2015
VIEW 2 EXCERPTS

B cells in chronic graft-versus-host disease.

  • Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • 2015